Intravenous injection of a foamy virus vector to correct canine SCID-X1

34Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Current approaches to hematopoietic stem cell (HSC) gene therapy involve the collection and ex vivomanipulation ofHSCs, a process associated with loss of stemcellmultipotency and engraftment potential. An alternative approach for correcting blood-related diseases is the direct intravenous administration of viral vectors, so-called in vivo gene therapy. In this study,weevaluated the safety and efficacy of in vivo gene therapy using a foamy virus vector for the correction of canine X-linked severe combined immunodeficiency (SCID-X1). In newborn SCID-X1 dogs, injection of a foamy virus vector expressing the human IL2RG gene resulted in an expansion of lymphocytes expressing the common γ chain and the development of CD3+ T lymphocytes. CD3+ cells expressed CD4 and CD8 coreceptors, underwent antigen receptor gene rearrangement, and demonstrated functional maturity in response to T-cell mitogens. Retroviral integration site analysis in 4 animals revealed a polyclonal pattern of integration in all dogs with evidence for dominant clones. These results demonstrate that a foamy virus vector can be administered with therapeutic benefit in the SCID-X1 dog, a clinically relevant preclinical model for in vivo gene therapy. © 2014 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Burtner, C. R., Beard, B. C., Kennedy, D. R., Wohlfahrt, M. E., Adair, J. E., Trobridge, G. D., … Kiem, H. P. (2014). Intravenous injection of a foamy virus vector to correct canine SCID-X1. Blood, 123(23), 3578–3584. https://doi.org/10.1182/blood-2013-11-538926

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free